CaaMTech
CaaMTech is a pharmaceutical drug discovery company that creates and optimizes small-molecule, psychedelic-inspired therapeutics, including novel tryptamines, for mental health conditions. It studies how chemical structure relates to biological activity and screens compounds for safety and efficacy, aiming to develop medicines with desired effects and fewer unwanted side effects.
Facts
- HQ
- Issaquah, WA, US
- Sectors
- Pharmaceutical Manufacturing
- Founded
- 2019
- Employees
- 7
Is this your organization? Claim it
GeekWire's Top Tech Stories for Sept. 14, 2025: Amazon Ends Commingling, Apple Acquires WhyLabs, Seattle Mayoral Candidate Katie Wilson Discusses Tech and Taxes
The most popular tech stories on GeekWire for the week of Sept. 14, 2025, include Amazon ending its commingling policy, Seattle mayoral candidate Katie Wilson's views on taxes and tech, Apple acquiring Seattle startup WhyLabs, and several startup funding and leadership updates.
Seattle-area CaaMTech Raises $22M to Develop Novel Tryptamines, Aiming for Human Testing
Seattle-area startup CaaMTech raised $22 million to develop synthesized tryptamine compounds similar to those in psilocybin and LSD, aiming to create defined formulations that maximize desired psychedelic effects and minimize side effects. The company says many of its novel agents are unscheduled in the U.S., and it plans to advance toward human testing amid growing investment and interest in psychedelics for mental-health treatments.
People
-
Andrew Chadeayne Founder & CEO
-
Davis Wuolle Executive, Chief Technology Officer & Chief Marketing Officer